During a recent interview at the Longevity Investors Conference, Dr. Charles Brenner was asked whether NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Life Changing Consumer Anecdotes) should be considered a longevity intervention. Here’s what he said (video and transcript below):

Beginning at the 4:10 mark below:

HOST:

“So let’s talk about technologies that are available in public today.

So you’ve got Nicotinamide Riboside “NR” (FAQs) (Life Changing Consumer Anecdotes).

You’re very famous for that (Dr. Brenner discovered NR as an NAD+ precursor vitamin).

What are your thoughts on this as an intervention for longevity today?

DR. Charles Brenner:

“Yeah, so I don’t call it a longevity drug.

But NAD is the central catalyst of metabolism.

Metabolism is kind of the life force of what we are and what we do.

And it (NAD) declines in aging.

And our resiliency, and our ability to repair declines in aging.

So, there are 50 ongoing clinical trials (using NR).

There’s been positive signals in Parkinson’s and other neurodegenerative conditions.

Potentially, nearly a positive signal in fatty liver.

It’s clearly anti-inflammatory.

I’d like to see placebo-controlled trials in which we look at wound repair because that’s a discrete thing that we can measure.

I don’t think that you can really do a lifespan trial itself.

And I’m not entirely convinced by the trials that are only measured by biomarker reversion because, once again, if your intervention is acting on the epigenetic machinery then just reversing that machinery doesn’t tell you anything functional.

So, again, it’s an exciting time for NAD and there’s a lot of safety trials and functional trials that are in process”

Related:

FOLLOW us on Twitter @RaisingNAD